Abstract: A series of 5-alkylthio (2a-d), 4-arylideneamino (3a-d) and 4-arylideneamino-5-alkylthio derivatives (4a-f) of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole (1) were synthesized by alkylation of the parent compound with alkyl halides and condensation with aldehydes, respectively. Sulfanyl dimers 5a-d and 4-iminomethyl dimer 6 were correspondingly prepared by reaction with alkane dibromides and 1,4-diformylbenzene. Mannich base 7 was also synthesized by aminomethylation of the 3-sulfanyltriazole 1 at the N 1 position. The newly designed and synthesized substituted s-triazole derivatives were assayed for anti-HIV-1 activity by examination of their inhibition of HIV-1-induced cytopathogenicity in MT-4 cells and by determination of their inhibitory effect on HIV-1 reverse transcriptase. Compound 4e was found to be the most active inhibitor against HIV-1 replication in cell culture (EC 50 = 12 μM) and against HIV-1 reverse transcriptase (IC 50 = 43.5 μM), which provided a good lead for further optimization.
Introduction
The worldwide AIDS crisis continues, with some 43 million people infected by HIV-1 and 8,000 deaths every day in 2006. HIV-1 reverse transcriptase (RT) is a key enzyme in the HIV-1 replication process and has been a key target for developing anti-HIV drugs. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have found widespread use in HIV therapy in multidrug treatment regimes and in highly active antiretroviral therapy (HAART) [1] . However, the use of NNRTIs in the clinic still remains subject to the rapid emergence of drug resistance due to mutation of the HIV-RT enzyme and this limits therapeutic options [2] . There is therefore an urgent need to develop new high potency drugs against both the wild-type (WT) HIV-1 and the drug-resistant mutant strains [3] .
In recent years a variety of potential candidates have been developed, especially new structural NNRTI classes, in which some substituted five-member heterocyclic compounds have been reported to be active in inhibition of HIV-1 replication targeting the RT step, e.g. capravirine, an imidazole derivative (formerly known as S-1153 and AG-1549, Figure 1a ), is one of the most promising NNRTIs currently in clinical trials [4] . More recently, sulfanyltriazole derivatives (Figure 1b ), have been identified as potent HIV-1 NNRTIs with low nanomolar inhibitory activity for viruses with wild-type or K103N/Y181C [5, 6] . In order to explore the structure-activity relationships (SAR) of this novel scaffold, herein we describe the design, synthesis and anti-HIV-1 activities of a series of novel substituted N 4 -arylideneaminotriazole derivatives ( Figure 1c ). 
Results and Discussion
Compound 1, 4-amino-3-(2-furyl)-5-mercapto-4H-1,2,4-triazole, was prepared by a one-pot reaction, which started with the reaction of 2-furoic acid hydrazide with carbon disulfide in ethanolic potassium hydroxide, to form a potassium dithiocarbazinate intermediate, followed by a cyclocondensation with excess hydrazine to produce the s-triazole 1 as a white solid in good yield [7] . 2-furoic acid hydrazide in turn was synthesized from the corresponding 2-furoic acid ester by reaction with hydrazine hydrate. 5-Alkylthio derivatives 2a-d were prepared by the alkylation of compound 1 with alkyl halides in potassium hydroxide/ethanol solution (Scheme 1) [8, 9] .
Schiff's bases of 4-arylideneamino compounds 3a-d were obtained by the condensation reactions of compound 1 with different aldehydes in refluxing ethanol solutions in the presence of trace amounts of concentrated sulphuric acid [10] . The structures of these compounds 3 were confirmed by their 1 H-NMR spectra (DMSO-d 6 ), in which two signals appeared at low field. The lower one (δ 13-12 ppm), exchangeable with deuterium oxide, corresponds to the NH proton (tautomer of the SH one), and the other one (δ 10-9 ppm) is attributed to the N=CH-group proton. Similar conditions to those described for the preparation of compounds 2 and 3 were used for the preparation of 4-arylideneamino-5-alkylthio derivatives 4a-f (Scheme 1). In order to increase the molecular diversity and analyze the structure-activity relationships, we also synthesized some new symmetric dimeric derivatives. When 4-arylideneamino-3-(2-furyl)-5-mecapto-1,2,4-triazoles 3 were mixed with half a mole of an alkyl dibromide and a molar equivalent of potassium hydroxide in refluxing methanol, dimers of 1,2-{4-arylideneamino-5,5'-di(3-(2-furyl)-1,2,4-triazolyl)}-dithioethane 5a-d were obtained as light yellow crystals in good yield (Scheme 2). 4-Iminomethyl dimer 6 was prepared by the reaction of compound 1 with 1,4-diformylbenzene in the refluxing ethanol (Scheme 3). Aminomethylation of compound 3 with formaldehyde and secondary amines in ethanol media produced the Mannich base 7a in good yield (Scheme 4). An exception was compound 7b, which was not obtained when the Mannich reaction was carried out under refluxing conditions, and instead compound 8 was formed (Scheme 5). The structure of compound 8 was confirmed by the 1 H-NMR spectrum, in which no methylene protons signal from 1-dibutylamino groups was found, as well as confirmed by the elemental analysis and IR spectra. From the results, we determined that only compounds 4e and 3a exhibited significant inhibitory activity against HIV-1 replication in MT-4 cell culture, with EC 50 values of 12 μM and 68.3 μM, respectively, and that most of the compounds had lost their effectiveness, compared with the prototype sulfanyltriazole compounds, which is probably due to the substituents at positions 3, 4 and 5 of the triazole heterocycle, which did not allow the molecules to bind to HIV-1 RT in a "butterfly-like" conformation [12] . Compound 4e showed a moderate potency in the inhibition of HIV-1 RT, with an IC 50 value of 43.5 μM, which agrees well with the results obtained in the cell culture test, further verifying the mechanism of action of this kind of compounds in targeting the NNRTI site of HIV-1 RT.
Conclusions
In summary, a series of 5-alkylthio-(2a-d), 4-arylideneamino-(3a-d) and 4-arylideneamino-5-alkylthio derivatives (4a-f) of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole (1) were synthesized by alkylation with alkyl halides and condensation with aldehydes, respectively. Other derivatives such as sulfanyl dimers 5a-d, 4-iminomethyl dimer 6 and the Mannich base 7a were also prepared. The structures of all newly synthesized compounds were assigned on the basis of elemental analysis, 1 H-NMR and IR spectra. Some substituted s-triazole derivatives were assayed for anti-HIV-1 activity by inhibition of HIV-1-induced cytopathogenicity in MT-4 cells and by determination of the inhibitory effect on the HIV-1 RT. The results showed that compound 4e was an active inhibitor against HIV-1 replication in cell culture (EC 50 = 12 μM) and against HIV-1 RT (IC 50 = 43.5 μM), which provides a good lead for design and discovery of new high potent HIV-1 NNRTIs by structure-based molecular modification.
Experimental

General
All melting points were measured on a Reichert-Jung Kofler melting point apparatus and are uncorrected; Elementary analysis data were determined with a Heraeus CHN-RAPID instrument;
1 H-NMR spectra were recorded on a Bruker Avance 300 (300 MHz) or a Bruker Avance 600 (600 MHz) spectrometer. The solvents used were DMSO-d 6 or CDCl 3 , as indicated; chemical shifts δ are reported in ppm units relative to the internal tetramethylsilane (TMS) standard. The coupling constants are given in Hz, and the different signals are expressed using the standard abbreviations (s, singlet; d, doublet; t, triplet; m, mutiplet; etc). Infrared spectra (IR) were recorded as KBr disks on a Shimadzu IR-435 spectrometer. The assignment data are only the maximum value of the absorption peak. All compounds were routinely checked by TLC. Merck silica gel 60 was used for flash column chromatographic purification. Solvents were reagent grade and when necessary, were purified and dried by standard methods. Concentration of the reaction solutions involved the use of a rotary evaporator at reduced pressure.
General Procedure for the Preparation of Compounds 2
To a suspension of 4-amino-3-furyl-5-sulfanyl-1,2,4-triazole 1 (1 mmol) in ethanol (10 mL) was added dropwise at 0°C an aqueous solution of potassium hydroxide (2 mol·L -1 , 1 mmol). To this mixture the appropriate alkyl halide (1.2 mmol) was added dropwise with vigorous stirring, the temperature was allowed to raise to ambient (25°C) and the reaction was continued for 1-2 h. When the reaction was complete (as checked by TLC), water (20 mL) was added, and a white precipitate was formed, which was separated by filtration, washed with water, and recrystallized from the appropriate solvent. 
4-Amino-3-(2-furyl)-5-benzylthio-4H-1,2,4-triazole (2a
4-Amino-3-(2-furyl)-5-(3-methoxylbenzyl)thio-4H-1,2,4-triazole (2b
General Procedure for the Preparation of Compounds 3
A mixture of 4-amino-3-furyl-5-sulfanyl-1,2,4-triazole 1 (0.1 mmol) with an aromatic aldehyde in ethanol/water (2:1, 40 mL), was refluxed for about 3 h (checked by TLC). When the reaction solution had cooled down, the crude product was precipitated, collected by filtration and recrystallized from an appropriate solvent.
4-(5-Nitrofurylidene)amino-3-(2-furyl)-5-sulfanyl-4H-1,2,4-triazole (3a)
. This compound was prepared by the condensation of compound 1 with 5-nitro-2-furaldehyde diacetate in sulfuric acidethanol-water (0.1:1:2) solution, and purified by recrystallization from acetone/ethanol 
4-(4-Methoxybenzylidene)amino-3-(2-furyl)-5-sulfanyl-4H-1,2,4-triazole (3b
4-(4-Chlorobenzylidene)amino-3-(2-furyl)-5-sulfanyl-4H-1,2,4-triazole (3d
General Procedure for the Preparation of Compounds 4
To a suspension of 4-(arylidene)amino-3-furyl-5-sulfanyl-1,2,4-triazole 3 (1 mmol) in ethanol (10 mL) in ice bath was added dropwise an aqueous solution of KOH (2 mol·L -1 , 1 mmol) with vigorous stirring. When the solid was dissolved, an alkyl halide (1.2 mmol) was added dropwise, and the temperature was raised to ambient (25°C) and kept there for 1-2 h. When the reaction was complete (as indicated by TLC), it was then cooled and a white precipitate was formed, which was separated by filtration, washed with water and recrystallized from a suitable solvent. 
4-(5-Nitrofurylidene)amino-3-(2-furyl)-5-benzylthio-4H-1,2,4-triazole (4a
4-(5-Nitrofurylidene)amino-3-(2-furyl)-5-(4-cynobenzyl)thio-4H-1,2,4-triazole (4c)
.
4-(5-Nitro-2-furylmethylidene)amino-3-(2-furyl)-5-(ethoxylcarbonyl)methylthio-4H-1,2,4-triazole
4-(3,4-Dimethoxylphenylidene)amino-3-(2-furyl)-5-benzylthio-4H-1,2,4-triazole (4e
General Procedure for the Preparation of Compounds 5
To a suspension of 4-(arylidene)amino/amino-3-furyl-5-sulfanyl-1,2,4-triazole 1 or 3 (1 mmol) in ethanol (10 mL) in an ice bath was added dropwise an aqueous solution of KOH (2 mol·L -1 , 1 mmol) with vigorous stirring. When the solid was dissolved, the appropriate alkyl dihalide (0.5 mmol) was added dropwise and the temperature was allowed to raise at 25°C for 1 h, then the reaction solution was refluxed for 1-2 h. (checked by TLC). The product was separated by flash column chromatography with suitable eluents and further purified by recrystallization from an appropriate solvent. 
1,2-bis[(4-Amino-3-(2-furyl)-4H-1,2,4-triazol)-5-yl]dithioethane (5a
Preparation of 4-[2-(5-nitro)furylmethylidene]amino-3-(2-furyl)-5-mercapto-piperidylmethyl-4H-1,2,4-triazole (7a).
Compound 3a (10 mmol) was dissolved in a mixed ethanol and dioxane solvent (2:1, 90 mL), then formaldehyde (40%, 1.5 mL) and piperidine (10 mmol) in ethanol (100 mL) were added to this solution. The mixture was stirred for 1-2 h and then kept overnight at room temperature. The solid was collected by filtration and recrystallized from a mixture of ethanol and dioxane (2:1) to yield the title compound 7a; yield: 80%; mp: 195-197°C; 1 H-NMR (600 MHz, DMSO-d 6 ) δ: 10.28
